Showing posts with label Cerulean Pharma (CERU). Show all posts
Showing posts with label Cerulean Pharma (CERU). Show all posts
Wednesday, August 13, 2014
Monday, June 23, 2014
Cerulean Pharma (CERU) began trading on the NASDAQ on 10 April 2014
Cerulean Pharma Inc. is a clinical-stage oncology-focused company applying its tumor targeting platform. The Company’s nanopharmaceutical product candidates consist of polymers that are linked to anti-cancer therapeutics, or payloads. Its lead product candidate, CRLX101, is in Phase II clinical development and has the potential to address cancer therapies. CRLX301, the second product candidate, is a nanopharmaceutical with docetaxel, a microtubule stabilizer, as its anti-cancer payload. The clinical development of CRLX101 is focused on cancer indications. A two-part Phase II open-label IST of CRLX101 is being conducted in patients with relapsed ovarian cancer. CRLX301 is designed to act as a tubulin inhibitor, capitalizes on its payload, docetaxel.
Address
5th Floor, 840 Memorial Drive
CAMBRIDGE, MA 02139
United States
CAMBRIDGE, MA 02139
United States
Website
http://ceruleanrx.comKey stats and ratios
| Q1 (Mar '14) | 2013 | |
| Net profit margin | -6200.00% | -285716.70% |
| Operating margin | -6293.62% | -264333.30% |
| EBITD margin | - | -261050.00% |
| Return on average assets | -125.13% | -140.01% |
| Return on average equity | - | - |
| Employees | 21 |
Subscribe to:
Posts (Atom)